Stem definition | Drug id | CAS RN |
---|---|---|
halogenated compounds used as general inhalation anaesthetics | 1493 | 26675-46-7 |
None
None
Date | Agency | Company | Orphan |
---|---|---|---|
Dec. 18, 1979 | FDA | BAXTER HLTHCARE |
MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
---|---|---|---|---|---|---|
Mitochondrial DNA mutation | 166.34 | 59.77 | 26 | 2385 | 396 | 63486215 |
Propofol infusion syndrome | 150.95 | 59.77 | 27 | 2384 | 956 | 63485655 |
Intra-abdominal pressure increased | 125.59 | 59.77 | 19 | 2392 | 230 | 63486381 |
Pneumatosis | 122.08 | 59.77 | 20 | 2391 | 415 | 63486196 |
Gene mutation | 118.72 | 59.77 | 24 | 2387 | 1641 | 63484970 |
Blood gases abnormal | 116.51 | 59.77 | 21 | 2390 | 776 | 63485835 |
Intestinal ischaemia | 105.65 | 59.77 | 29 | 2382 | 7439 | 63479172 |
Necrosis ischaemic | 102.06 | 59.77 | 19 | 2392 | 841 | 63485770 |
CSF oligoclonal band present | 95.42 | 59.77 | 16 | 2395 | 384 | 63486227 |
Apnoea | 94.53 | 59.77 | 27 | 2384 | 7995 | 63478616 |
Multiple-drug resistance | 91.66 | 59.77 | 24 | 2387 | 5146 | 63481465 |
Hyperthermia malignant | 89.95 | 59.77 | 17 | 2394 | 817 | 63485794 |
Pleocytosis | 89.72 | 59.77 | 17 | 2394 | 828 | 63485783 |
Delayed recovery from anaesthesia | 84.94 | 59.77 | 16 | 2395 | 755 | 63485856 |
Systemic inflammatory response syndrome | 80.29 | 59.77 | 22 | 2389 | 5599 | 63481012 |
Metabolic acidosis | 78.69 | 59.77 | 37 | 2374 | 45032 | 63441579 |
Blood lactic acid increased | 75.25 | 59.77 | 22 | 2389 | 7064 | 63479547 |
Exposure during pregnancy | 74.13 | 59.77 | 55 | 2356 | 155492 | 63331119 |
Post procedural complication | 70.76 | 59.77 | 26 | 2385 | 17048 | 63469563 |
Shock | 62.73 | 59.77 | 26 | 2385 | 23437 | 63463174 |
Arrhythmia | 62.54 | 59.77 | 30 | 2381 | 38110 | 63448501 |
Ultrasound ovary abnormal | 61.23 | 59.77 | 9 | 2402 | 88 | 63486523 |
Perforation | 60.76 | 59.77 | 13 | 2398 | 1170 | 63485441 |
Hypotension | 59.89 | 59.77 | 62 | 2349 | 272542 | 63214069 |
MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
---|---|---|---|---|---|---|
Hyperthermia malignant | 269.17 | 53.48 | 54 | 2161 | 2123 | 34952593 |
Apnoea | 111.50 | 53.48 | 33 | 2182 | 6631 | 34948085 |
Hypotension | 104.11 | 53.48 | 96 | 2119 | 221553 | 34733163 |
Intestinal ischaemia | 102.20 | 53.48 | 32 | 2183 | 7762 | 34946954 |
Post procedural complication | 101.85 | 53.48 | 35 | 2180 | 11353 | 34943363 |
Necrosis ischaemic | 99.08 | 53.48 | 17 | 2198 | 275 | 34954441 |
Superinfection | 86.64 | 53.48 | 22 | 2193 | 2497 | 34952219 |
Fear | 81.38 | 53.48 | 29 | 2186 | 10447 | 34944269 |
Anhedonia | 78.39 | 53.48 | 26 | 2189 | 7559 | 34947157 |
Mucosal ulceration | 78.28 | 53.48 | 17 | 2198 | 978 | 34953738 |
Systemic inflammatory response syndrome | 77.42 | 53.48 | 25 | 2190 | 6684 | 34948032 |
Injury | 74.99 | 53.48 | 33 | 2182 | 20654 | 34934062 |
Renal injury | 68.49 | 53.48 | 26 | 2189 | 11169 | 34943547 |
Emotional distress | 61.08 | 53.48 | 26 | 2189 | 15000 | 34939716 |
Blood lactic acid increased | 53.65 | 53.48 | 19 | 2196 | 6709 | 34948007 |
MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
---|---|---|---|---|---|---|
Hyperthermia malignant | 340.45 | 48.16 | 68 | 4555 | 2849 | 79736916 |
Intestinal ischaemia | 220.16 | 48.16 | 64 | 4559 | 13206 | 79726559 |
Necrosis ischaemic | 192.63 | 48.16 | 36 | 4587 | 1054 | 79738711 |
Hypotension | 157.47 | 48.16 | 158 | 4465 | 440159 | 79299606 |
Mitochondrial DNA mutation | 154.61 | 48.16 | 26 | 4597 | 407 | 79739358 |
Systemic inflammatory response syndrome | 154.05 | 48.16 | 47 | 4576 | 11418 | 79728347 |
Propofol infusion syndrome | 142.73 | 48.16 | 31 | 4592 | 1952 | 79737813 |
Blood lactic acid increased | 120.57 | 48.16 | 40 | 4583 | 12704 | 79727061 |
Intra-abdominal pressure increased | 115.29 | 48.16 | 19 | 4604 | 261 | 79739504 |
Fear | 113.30 | 48.16 | 44 | 4579 | 21942 | 79717823 |
Metabolic acidosis | 112.40 | 48.16 | 66 | 4557 | 82463 | 79657302 |
Renal injury | 109.46 | 48.16 | 40 | 4583 | 16887 | 79722878 |
Delayed recovery from anaesthesia | 108.43 | 48.16 | 24 | 4599 | 1649 | 79738116 |
Anhedonia | 106.81 | 48.16 | 38 | 4585 | 14860 | 79724905 |
Gene mutation | 102.19 | 48.16 | 25 | 4598 | 2661 | 79737104 |
Blood gases abnormal | 99.38 | 48.16 | 21 | 4602 | 1159 | 79738606 |
Pneumatosis | 99.32 | 48.16 | 20 | 4603 | 869 | 79738896 |
CSF oligoclonal band present | 87.82 | 48.16 | 16 | 4607 | 405 | 79739360 |
Emotional distress | 76.41 | 48.16 | 40 | 4583 | 39929 | 79699836 |
Respiratory acidosis | 74.37 | 48.16 | 27 | 4596 | 11173 | 79728592 |
Superinfection | 74.02 | 48.16 | 22 | 4601 | 4880 | 79734885 |
Pleocytosis | 73.50 | 48.16 | 17 | 4606 | 1422 | 79738343 |
Injury | 70.40 | 48.16 | 48 | 4575 | 77448 | 79662317 |
Unevaluable event | 69.22 | 48.16 | 42 | 4581 | 55543 | 79684222 |
Mucosal ulceration | 69.05 | 48.16 | 17 | 4606 | 1856 | 79737909 |
Anaesthetic complication | 66.58 | 48.16 | 18 | 4605 | 2841 | 79736924 |
Blood creatine phosphokinase increased | 60.17 | 48.16 | 41 | 4582 | 66049 | 79673716 |
Procedural hypotension | 57.91 | 48.16 | 15 | 4608 | 2008 | 79737757 |
Ultrasound ovary abnormal | 57.42 | 48.16 | 9 | 4614 | 88 | 79739677 |
Bradycardia | 56.24 | 48.16 | 53 | 4570 | 135504 | 79604261 |
Procedural complication | 55.83 | 48.16 | 20 | 4603 | 7963 | 79731802 |
Shock | 54.45 | 48.16 | 33 | 4590 | 43515 | 79696250 |
Renal failure | 53.58 | 48.16 | 62 | 4561 | 200906 | 79538859 |
Perforation | 52.85 | 48.16 | 13 | 4610 | 1413 | 79738352 |
Left ventricular hypertrophy | 52.72 | 48.16 | 21 | 4602 | 11170 | 79728595 |
Multiple-drug resistance | 50.26 | 48.16 | 19 | 4604 | 8789 | 79730976 |
Multiple organ dysfunction syndrome | 49.84 | 48.16 | 47 | 4576 | 120199 | 79619566 |
None
Source | Code | Description |
---|---|---|
ATC | N01AB06 | NERVOUS SYSTEM ANESTHETICS ANESTHETICS, GENERAL Halogenated hydrocarbons |
MeSH PA | D000777 | Anesthetics |
MeSH PA | D018685 | Anesthetics, Inhalation |
MeSH PA | D002491 | Central Nervous System Agents |
MeSH PA | D002492 | Central Nervous System Depressants |
CHEBI has role | CHEBI:38870 | inhalation anesthetics |
FDA EPC | N0000175681 | General Anesthetic |
FDA PE | N0000175975 | General Anesthesia |
Disease | Relation | SNOMED_ID | DOID |
---|---|---|---|
General anesthesia | indication | 50697003 | |
Hyperkalemia | contraindication | 14140009 | |
Low blood pressure | contraindication | 45007003 | |
Duchenne muscular dystrophy | contraindication | 76670001 | DOID:11723 |
Disease of liver | contraindication | 235856003 | DOID:409 |
Malignant hyperthermia | contraindication | 405501007 |
Species | Use | Relation |
---|---|---|
Dogs | Induction and maintenance of general anesthesia | Indication |
Horses | Induction and maintenance of general anesthesia | Indication |
Product | Applicant | Ingredients |
---|---|---|
IsoFlo | Zoetis Inc. | 1 |
Isoflurane, USP | Dechra Veterinary Products LLC | 1 |
ATTANE | Piramal Critical Care Inc. | 1 |
Isoflurane, USP | Piramal Enterprises Ltd. | 1 |
None
None
None
Target | Class | Pharos | UniProt | Action | Type | Activity value (-log[M]) | Mechanism action | Bioact source | MoA source |
---|---|---|---|---|---|---|---|---|---|
GABA-A receptor; anion channel | Ion channel | POSITIVE ALLOSTERIC MODULATOR | CHEMBL | CHEMBL | |||||
Potassium channel subfamily K member 2 | Ion channel | OPENER | CHEMBL | CHEMBL | |||||
Potassium channel subfamily K member 3 | Ion channel | OPENER | CHEMBL | CHEMBL | |||||
Potassium channel subfamily K member 9 | Ion channel | OPENER | CHEMBL | CHEMBL | |||||
Potassium channel subfamily K member 10 | Ion channel | OPENER | CHEMBL | CHEMBL | |||||
Potassium channel subfamily K member 18 | Ion channel | OPENER | CHEMBL | CHEMBL | |||||
Glycine receptor (alpha-1/beta) | Ion channel | POSITIVE MODULATOR | CHEMBL | CHEMBL | |||||
5-hydroxytryptamine receptor 2B | GPCR | Ki | 5.11 | PDSP |
ID | Source |
---|---|
4019107 | VUID |
N0000147364 | NUI |
D00545 | KEGG_DRUG |
4019107 | VANDF |
C0022180 | UMLSCUI |
CHEBI:6015 | CHEBI |
ICF | PDB_CHEM_ID |
CHEMBL1256 | ChEMBL_ID |
DB00753 | DRUGBANK_ID |
D007530 | MESH_DESCRIPTOR_UI |
3763 | PUBCHEM_CID |
3286 | INN_ID |
2505 | IUPHAR_LIGAND_ID |
CYS9AKD70P | UNII |
6026 | RXNORM |
284 | MMSL |
4326 | MMSL |
4926 | MMSL |
d00267 | MMSL |
001391 | NDDF |
387368002 | SNOMEDCT_US |
66492008 | SNOMEDCT_US |
Product | Category | Ingredients | NDC | Form | Quantity | Route | Marketing | Label |
---|---|---|---|---|---|---|---|---|
FORANE | HUMAN PRESCRIPTION DRUG LABEL | 1 | 10019-360 | INHALANT | 1 mL | RESPIRATORY (INHALATION) | NDA | 23 sections |
FORANE | HUMAN PRESCRIPTION DRUG LABEL | 1 | 10019-360 | INHALANT | 1 mL | RESPIRATORY (INHALATION) | NDA | 23 sections |
FORANE | HUMAN PRESCRIPTION DRUG LABEL | 1 | 10019-360 | INHALANT | 1 mL | RESPIRATORY (INHALATION) | NDA | 23 sections |
Isoflurane | HUMAN PRESCRIPTION DRUG LABEL | 1 | 12164-012 | LIQUID | 1 mL | RESPIRATORY (INHALATION) | ANDA | 22 sections |
Terrell | HUMAN PRESCRIPTION DRUG LABEL | 1 | 66794-011 | LIQUID | 1 mL | RESPIRATORY (INHALATION) | ANDA | 13 sections |
Terrell | HUMAN PRESCRIPTION DRUG LABEL | 1 | 66794-011 | LIQUID | 1 mL | RESPIRATORY (INHALATION) | ANDA | 13 sections |
Terrell | HUMAN PRESCRIPTION DRUG LABEL | 1 | 66794-011 | LIQUID | 1 mL | RESPIRATORY (INHALATION) | ANDA | 13 sections |
Terrell | HUMAN PRESCRIPTION DRUG LABEL | 1 | 66794-011 | LIQUID | 1 mL | RESPIRATORY (INHALATION) | ANDA | 13 sections |
Isoflurane | HUMAN PRESCRIPTION DRUG LABEL | 1 | 66794-017 | LIQUID | 1 mL | RESPIRATORY (INHALATION) | ANDA | 21 sections |
Isoflurane | HUMAN PRESCRIPTION DRUG LABEL | 1 | 66794-017 | LIQUID | 1 mL | RESPIRATORY (INHALATION) | ANDA | 21 sections |
Isoflurane | HUMAN PRESCRIPTION DRUG LABEL | 1 | 66794-017 | LIQUID | 1 mL | RESPIRATORY (INHALATION) | ANDA | 21 sections |
Terrell | HUMAN PRESCRIPTION DRUG LABEL | 1 | 66794-019 | LIQUID | 1 mL | RESPIRATORY (INHALATION) | ANDA | 21 sections |
Terrell | HUMAN PRESCRIPTION DRUG LABEL | 1 | 66794-019 | LIQUID | 1 mL | RESPIRATORY (INHALATION) | ANDA | 21 sections |
Terrell | HUMAN PRESCRIPTION DRUG LABEL | 1 | 66794-019 | LIQUID | 1 mL | RESPIRATORY (INHALATION) | ANDA | 21 sections |
Isoflurane | HUMAN PRESCRIPTION DRUG LABEL | 1 | 66794-020 | LIQUID | 1 mL | RESPIRATORY (INHALATION) | ANDA | 14 sections |
Isoflurane | HUMAN PRESCRIPTION DRUG LABEL | 1 | 66794-020 | LIQUID | 1 mL | RESPIRATORY (INHALATION) | ANDA | 14 sections |
Isoflurane | HUMAN PRESCRIPTION DRUG LABEL | 1 | 66794-020 | LIQUID | 1 mL | RESPIRATORY (INHALATION) | ANDA | 14 sections |
Isoflurane | HUMAN PRESCRIPTION DRUG LABEL | 1 | 66794-020 | LIQUID | 1 mL | RESPIRATORY (INHALATION) | ANDA | 14 sections |